NextCell Pharma's clinical trial on the TV3 Diabetes gala

The stem cell company NextCell Pharma (“NXTCL”) announces that the company and its stem cell bank Cellaviva are highlighted by Karolinska Institutet Innovations as a positive example in its Jubilee book “20 year of innovation @ Karolinska Institutet”. Of nearly 400 innovations, NextCell and a further 19 examples have been selected to represent the social benefits that research of KI has contributed during the past 20 years. Cellaviva was founded by researchers at Karolinska Institutet with help from Karolinska Institutet Innovations AB. The company became the first private stem cell bank in

NextCell Pharma AB ("NextCell") announces today, that during the last few months the company has engaged in an array of valuable activities and collaborations. NextCell is active in the “SweLife ATMP health economics and business models” project led by RISE and the “Visions Driven Health” project, both funded by Vinnova. The work conducted in the projects is a collaborative effort between different types of stakeholders, such as SMEs, big pharma and county councils, all with the common goal of improving the Swedish conditions for innovative cell therapies. The latest development is that

NextCell Pharma AB ("NextCell") gives the market updated information before its presentation at ProHearing later today by CEO, Mathias Svahn. Recruitment of patients with type-1 diabetes in the Phase II part of the ProTrans-1 clinical trial with the drug candidate ProTrans is ongoing. An application for a new trial, ProTrans-repeat, has been submitted and Cellaviva's customer inflow has been increasing. ProTrans-1, NXTCL's ongoing clinical trial for the treatment of type-1 diabetes, is divided into two parts, the first being a three-step dose escalation with three patients in each step, a

NextCell Pharma AB ("NXTCL") announces that Invest Stockholm has now placed NXTCL on the Life Science Hotlist. The Stockholm-Uppsala Life Science Investment Hotlist is curated by Invest Stockholm and lists the most promising and innovative companies active in the field of life science. NXTCL with both its stem cell banking and drug development business is an ideal candidate for this list. The company develops novel treatments with stem cells from the umbilical cord. In umbilical cord and umbilical cord tissue there are young and viable stem cells that can be collected without any medical

NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 2019 National Conference on Clinical Studies. The conference, which is held in Malmö and arranged by the national initiative Clinical Studies Sweden, a collaboration between Vetenskapsrådet (Swedish Research Council) and Sweden´s six healthcare regions, brings together researchers, politicians, and others who are active in the Life Science area. The scope of the event is knowledge exchange and networking, with the topic for the year being “The Value of Clinical studies”. Examples of issues

Stem cell company NextCell Pharma AB (”NXTCL”) announces that Cellaviva’s sales has increased significantly from November 2018 to January 2019, as compared to the corresponding months previous year. It is partly a result of an increasing interest in stem cell saving in Sweden, and partly due to the expansion into Denmark. Cellaviva offers new parents the opportunity to save their child´s stem cells for therapeutic treatment of diseases the family has suffered from, or risk being affected of in the future. Stem cells are collected from the umbilical cord after the umbilical cord has been cut

First quarter (2018-09-01 till 2018-11-30) · Net sales amounted to SEK 73,745 (158,354). Apart from the accrual effect, sales increased by 7 %. · Operating result amounted to SEK -5,440,809 (-3,210,815).                         · Earnings per share* amounted to SEK -0.51 (-0.38). · Cash and bank amounted to SEK 10,437,405 (13,365,659). · Solidity** amounted to 87 (59) %. **Result per share: operating results divided by the average number of shares. Average number of shares for the first quarter of 2018/2019: 10,693,960 shares (8,505,425). Number of shares in NextCell as

NextCell Pharma AB ("NextCell") hereby announces that they today have reached a significant milestone as they have now initiated the second part of the ProTrans-1 clinical trial. In addition to safety, clinical efficacy is evaluated, e.g. whether the patient's own insulin production improves 12 months after treatment with ProTrans compared to placebo. The phase-II part is randomized, double-blind, placebo-controlled which means that neither the patient nor the doctor knows what treatment the patient is receiving. So far, two patients have undergone treatment. In total, 15 patients will be